Coagulation behaviour at starting and at stopping adjuvant post-operative tamoxifen (T) in 38 subjects with breast cancer (BC) Year: 2003 Category: Adjuvant Therapy Abstract No: 349 Author(s): G. Todeschini, G. Cartei, D. Pastorelli, F. Zustovich, F. Salmaso, E. Vattemi, S. Binato, S. Zovato; Department of Hematology-Verona, Verona, Italy; General Oncology, Ussl 16 Padova, Padova, Italy Abstract: Rationale: T is largely used as an adjuvant therapy after complete removal of primary BC. T may negatively influence the coagulation behaviour. Vein thrombosys may occure, even if rarely. Patients and tests: We have prospectly studied 38 patients treated with oral 20 mg/day T for 5 years: 37 women aged from 41 to 77 y.o. (meanąSD: 56.97ą9.50) and a male patient aged 58 y.o. Initial age: 54.38ą9.68; age at therapy end: 59.3ą8.95. Tests (see table) (meanąSD values) were measured before starting (B1) and after stopping (B2) the T and at intermediate times. Also the pharmacokinets of T has been studied (data not shown). (table) Student paired t-test has been used: p<0.0001: fibrinogen, b vs a// p<0.001: fibrinogen, c vs a; ATIII, c vs a; C-protein, c vs b// p<0.01: fibrinogen, c vs b; C-protein, c vs a; S-protein, c vs b, c vs a, b vs a, e vs d; ATIII, e vs d// p<0.05: fibrinogen, e vs d, PTT, e vs d; C-protein, e vs d. Conclusions: T induced a consistent modification of the coagulation in terms of fibrinogen consumption. It resolved after discontinuing therapy. Caution in the use of primary preventive T therapy is mandatory. Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.